Becton Dickinson and Company (BDX)vsCuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)
BDX
Becton Dickinson and Company
$151.16
+1.07%
HEALTHCARE · Cap: $39.80B
CUPR
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares
$2.43
-10.99%
HEALTHCARE · Cap: $7.59M
Smart Verdict
WallStSmart Research — data-driven comparison
Becton Dickinson and Company generates 44551912% more annual revenue ($22.23B vs $49,890). BDX leads profitability with a 5.1% profit margin vs 0.0%. BDX earns a higher WallStSmart Score of 65/100 (B-).
BDX
Strong Buy65
out of 100
Grade: B-
CUPR
Avoid30
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+9.9%
Fair Value
$200.45
Current Price
$151.16
$49.29 discount
Intrinsic value data unavailable for CUPR.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Earnings expanding 28.6% YoY
Revenue surging 267.4% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Moderate valuation
ROE of 4.7% — below average capital efficiency
5.1% margin — thin
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -92.4% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : BDX
The strongest argument for BDX centers on Price/Book, EPS Growth. PEG of 1.11 suggests the stock is reasonably priced for its growth.
Bull Case : CUPR
The strongest argument for CUPR centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 267.4% demonstrates continued momentum.
Bear Case : BDX
The primary concerns for BDX are P/E Ratio, Return on Equity, Profit Margin.
Bear Case : CUPR
The primary concerns for CUPR are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
BDX profiles as a value stock while CUPR is a hypergrowth play — different risk/reward profiles.
CUPR is growing revenue faster at 267.4% — sustainability is the question.
BDX generates stronger free cash flow (546M), providing more financial flexibility.
Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
BDX scores higher overall (65/100 vs 30/100). Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Becton Dickinson and Company
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.
Visit Website →Cuprina Holdings (Cayman) Limited Class A Ordinary Shares
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Cuprina Holdings (Cayman) Limited, a biomedical and biotechnology company, focuses on the development and commercialization of products for the management of chronic wounds.
Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?